.jpg)
1 hour ago
3
Article content
POWAY, Calif., June 18, 2026 (GLOBE NEWSWIRE) — Diazyme Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Diazyme Lipoprotein(a) Molarity Assay. This clearance enables clinical laboratories to use the assay for the quantitative determination of lipoprotein-Lp(a) levels in human serum and plasma, reported in molar units (nmol/L).
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
“FDA 510(k) clearance of our Lipoprotein(a) Molarity Assay represents a major step forward in cardiovascular risk assessment. For decades, variability in Lp(a) measurement due to apo(a) isoform heterogeneity has limited clinical comparability and interpretation across laboratories and platforms.
Article content
Article content
Article content
“Our assay directly addresses this challenge by providing an isoform-independent measurement in molar units, enabling consistent and clinically meaningful quantification of Lipoprotein(a) across diverse patient populations. This is critical for improving risk stratification in cardiovascular disease, where Lp(a) is an established independent risk factor,” said Chong Yuan, Ph.D., Managing Director of Diazyme Laboratories, Inc.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
“We believe this clearance will help accelerate broader clinical adoption of standardized Lp(a) testing and support clinicians in identifying high-risk patients who may otherwise go undetected using conventional mass-based or isoform-sensitive methods.”
Article content
About Diazyme Laboratories, Inc.
Article content
Diazyme Laboratories, Inc. is located in Poway, California. Diazyme uses its proprietary enzyme and immunoassay technologies to develop diagnostic test reagents run on automated chemistry analyzers and chemiluminescence instruments in user-friendly formats. Diazyme is a cGMP and ISO 13485 certified medical device manufacturer. Information regarding Diazyme’s technology and products can be found on its website at www.diazyme.com.
Article content
For Further Information Contact:
Article content
Sales
Tel: 858-455-4768
Email: [email protected]
Support
Email: [email protected]
Article content
Article content
Article content
Article content
Article content
Article content
English (US)